MetaCap

Penumbra (PEN) vs Insulet (PODD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Penumbra (PEN) has outperformed Insulet (PODD) over the past year, gaining 10.6% versus a loss of 59.8%. Over five years, PEN leads with a +27.6% price change compared with -54.9% for PODD. Penumbra is the larger company by market cap ($12.58 billion vs $9.24 billion), about 1.4 times the size, while Insulet is growing revenue faster (+30.7% vs +17.5%).

On valuation, Insulet trades at a lower forward P/E (16.8x vs 53.1x for Penumbra). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus 9.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PEN+10.63%PODD-59.79%
+29%-18%-65%
Nov 21, 20251 yearNov 20, 2026
PEN+21.79%PODD-55.76%
+42%-10%-61%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PEN versus PODD key metrics
MetricPENPODD
Share price$319.12$133.17
Market cap$12.58B$9.24B
1-day change-0.28%-2.96%
YTD return+2.64%-53.15%
1-year return+10.63%-59.79%
5-year return+27.57%-54.92%
P/E ratio (TTM)80.3821.76
Forward P/E53.0916.83
EPS (TTM)$3.97$6.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.40B$2.71B
Revenue growth (YoY)+17.50%+30.73%
Net income (latest FY)$177.69M$247.10M
Gross margin67.14%71.63%
Operating margin13.48%17.50%
Net margin12.66%9.12%
52-week high$362.41$342.13
52-week low$284.95$126.40
Distance from 52-week high-11.95%-61.08%
Analyst consensusholdbuy
Avg. price target upside+13.61%+33.60%
Average volume358.21K1.61M
Shares outstanding39.41M69.37M
Employees4,7005,400
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PEN has outperformed PODD by 70.4 percentage points over the past year.
  • Penumbra trades at a higher earnings multiple (80.4x vs 21.8x trailing P/E).
  • Insulet grew revenue faster in its latest fiscal year (+30.73% vs +17.50%).

About Penumbra

PEN stock →

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

Health Care · Medical/Dental Instruments · 4,700 employees

About Insulet

PODD stock →

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Health Care · Medical/Dental Instruments · 5,400 employees

PEN vs PODD FAQ

Which is bigger, Penumbra or Insulet?

Penumbra (PEN) is larger, with a market capitalization of $12.58B compared with $9.24B for Insulet (PODD).

Which stock has performed better over the past year, PEN or PODD?

PEN returned +10.63% over the past 12 months, compared with -59.79% for PODD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, PEN or PODD?

PODD has the lower trailing P/E at 21.8, versus 80.4 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Penumbra and Insulet in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons